Dihydroxyphenylisoindoline Amides as Orally Bioavailable Inhibitors of the Heat Shock Protein 90 (Hsp90) Molecular Chaperone
摘要:
The discovery and optimization of potency and metabolic stability of a novel class of dihyroxyphenylisoindoline amides as Hsp90 inhibitors are presented. Optimization of a screening hit using structure-based design and modification of log D and chemical structural features led to the identification of a class of orally bioavailable non-quinone-containing Hsp90 inhibitors. This class is exemplified by 14 and 15, which possess improved cell potency and pharmacokinetic profiles compared with the original screening hit.
2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS
申请人:Kung Pei-Pei
公开号:US20100041681A1
公开(公告)日:2010-02-18
The present invention is directed to compounds of formula (I),
or pharmaceutically acceptable salts thereof, their synthesis, and their use as HSP-90 inhibitors.
本发明涉及式(I)的化合物,或其药学上可接受的盐,其合成以及作为HSP-90抑制剂的用途。
[EN] 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS<br/>[FR] COMPOSÉS 2-AMINO PYRIMIDINE COMME INHIBITEURS PUISSANTS DE L'HSP-90
申请人:PFIZER
公开号:WO2010018481A1
公开(公告)日:2010-02-18
The present invention is directed to compounds of Formula (I), or pharmaceutically acceptable salts thereof, their synthesis, and their use as HSP-90 inhibitors in the treatment of proliferative diseases, e.g. cancer.
The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as HSP-90 inhibitors.
本发明涉及式(I)化合物及其药学上可接受的盐、其合成以及作为HSP-90抑制剂的使用。
2-amino pyrimidine compounds as potent HSP-90 inhibitors
申请人:Pfizer Inc.
公开号:US08080556B2
公开(公告)日:2011-12-20
The present invention is directed to compounds of formula (I),
or pharmaceutically acceptable salts thereof, their synthesis, and their use as HSP-90 inhibitors.
本发明涉及式(I)化合物或其药学上可接受的盐,它们的合成以及它们作为HSP-90抑制剂的用途。
AMIDE RESORCINOL COMPOUNDS
申请人:Funk Lee Andrew
公开号:US20090215742A1
公开(公告)日:2009-08-27
The present invention is directed to compounds of formula (I),
and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as HSP-90 inhibitors.